Fluoxymesterone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Fluoxymesterone

Clinical data
ATC code	G03BA01 (WHO)
Pharmacokinetic data
Bioavailability	100% Oral
Metabolism	Hepatic
Elimination half-life	9.5 hours
Excretion	urine
Identifiers
IUPAC name 9-fluoro-11,17- dihydroxy-10,13,17- trimethyl-1,2,6,7,8,11,12,14,15,16- decahydrocyclopenta[a] phenanthren-3-one
CAS Number	76-43-7
PubChem CID	6446
DrugBank	APRD00981
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C20H29FO3
Molar mass	336.441 g/mol

WikiDoc Resources for Fluoxymesterone
Articles
Most recent articles on Fluoxymesterone Most cited articles on Fluoxymesterone Review articles on Fluoxymesterone Articles on Fluoxymesterone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Fluoxymesterone Images of Fluoxymesterone Photos of Fluoxymesterone Podcasts & MP3s on Fluoxymesterone Videos on Fluoxymesterone
Evidence Based Medicine
Cochrane Collaboration on Fluoxymesterone Bandolier on Fluoxymesterone TRIP on Fluoxymesterone
Clinical Trials
Ongoing Trials on Fluoxymesterone at Clinical Trials.gov Trial results on Fluoxymesterone Clinical Trials on Fluoxymesterone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Fluoxymesterone NICE Guidance on Fluoxymesterone NHS PRODIGY Guidance FDA on Fluoxymesterone CDC on Fluoxymesterone
Books
Books on Fluoxymesterone
News
Fluoxymesterone in the news Be alerted to news on Fluoxymesterone News trends on Fluoxymesterone
Commentary
Blogs on Fluoxymesterone
Definitions
Definitions of Fluoxymesterone
Patient Resources / Community
Patient resources on Fluoxymesterone Discussion groups on Fluoxymesterone Patient Handouts on Fluoxymesterone Directions to Hospitals Treating Fluoxymesterone Risk calculators and risk factors for Fluoxymesterone
Healthcare Provider Resources
Symptoms of Fluoxymesterone Causes & Risk Factors for Fluoxymesterone Diagnostic studies for Fluoxymesterone Treatment of Fluoxymesterone
Continuing Medical Education (CME)
CME Programs on Fluoxymesterone
International
Fluoxymesterone en Espanol Fluoxymesterone en Francais
Business
Fluoxymesterone in the Marketplace Patents on Fluoxymesterone
Experimental / Informatics
List of terms related to Fluoxymesterone

Fluoxymesterone (Halotestin) is an androgenic steroid that is only useful to a small select group of athletes who seeks very specific goals. Athletes tend to use it to increase strength and aggression in the gym or in competitions such as strongman contests, fighting (like boxing) or MMA. The lack of estrogenic activity makes Halotestin perfect for pre-fight usage – as weigh-ins would not be effected by water retention. Even in such an events, Fluoxymesterone usage is usually limited to mere few weeks rather than cycled like real steroids for months.

Fluoxymesterone (Halotestin) has poor binding to the AR. Studies have shown the effects to be mostly non-AR mediated. However, it is considered a very toxic oral drug, and a poor choice in most bodybuilding/steroid use applications.

The half life of Fluoxymesterone (Halotestin) is commonly misunderstood. The rumored belief is that 30-90 minutes is the half-life but this rumor is false, the half life of Fluoxymesterone is about 9.5 hours.

Further reading

Daniels, R. C. (February 1, 2003). The Anabolic Steroid Handbook. Richard C Daniels. p. 80. ISBN 0-9548227-0-6.

External links

• Fluoxymesterone and Health Treatments- PubMed Study